Rainbow Children's Medicare First Quarter 2026 Earnings: EPS Beats Expectations

July 28, 2025

Rainbow Children's Medicare (NSE:RAINBOW) First Quarter 2026 Results

Key Financial Results

Revenue: ₹3.53b (up 6.9% from 1Q 2025).
Net income: ₹535.0m (up 35% from 1Q 2025).
Profit margin: 15% (up from 12% in 1Q 2025). The increase in margin was driven by higher revenue.
EPS: ₹5.27 (up from ₹3.89 in 1Q 2025).

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

earnings-and-revenue-growth — NSEI:RAINBOW Earnings and Revenue Growth July 28th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Rainbow Children's Medicare EPS Beats Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 16%.

Looking ahead, revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Healthcare industry in India.

Performance of the Indian Healthcare industry.

The company's shares are up 2.0% from a week ago.

Balance Sheet Analysis

Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. See our latest analysis on Rainbow Children's Medicare's balance sheet health.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.